vs

Side-by-side financial comparison of Arcutis Biotherapeutics, Inc. (ARQT) and LATTICE SEMICONDUCTOR CORP (LSCC). Click either name above to swap in a different company.

LATTICE SEMICONDUCTOR CORP is the larger business by last-quarter revenue ($145.8M vs $129.5M, roughly 1.1× Arcutis Biotherapeutics, Inc.). Arcutis Biotherapeutics, Inc. runs the higher net margin — 13.4% vs -5.2%, a 18.7% gap on every dollar of revenue. On growth, Arcutis Biotherapeutics, Inc. posted the faster year-over-year revenue change (81.5% vs 9.3%). Over the past eight quarters, Arcutis Biotherapeutics, Inc.'s revenue compounded faster (61.6% CAGR vs 8.4%).

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.

Lattice Semiconductor Corporation is an American semiconductor company specializing in the design and manufacturing of low power field-programmable gate arrays (FPGAs). Headquartered in the Silicon Forest area of Hillsboro, Oregon, the company also has operations in San Jose, Calif., Shanghai, Manila, Penang, and Singapore. Lattice Semiconductor has more than 1000 employees and an annual revenue of more than $660 million as of 2022. The company was founded in 1983 and went public in 1989. It ...

ARQT vs LSCC — Head-to-Head

Bigger by revenue
LSCC
LSCC
1.1× larger
LSCC
$145.8M
$129.5M
ARQT
Growing faster (revenue YoY)
ARQT
ARQT
+72.2% gap
ARQT
81.5%
9.3%
LSCC
Higher net margin
ARQT
ARQT
18.7% more per $
ARQT
13.4%
-5.2%
LSCC
Faster 2-yr revenue CAGR
ARQT
ARQT
Annualised
ARQT
61.6%
8.4%
LSCC

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ARQT
ARQT
LSCC
LSCC
Revenue
$129.5M
$145.8M
Net Profit
$17.4M
$-7.6M
Gross Margin
91.0%
68.5%
Operating Margin
14.2%
30.7%
Net Margin
13.4%
-5.2%
Revenue YoY
81.5%
9.3%
Net Profit YoY
261.2%
14.6%
EPS (diluted)
$0.14
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARQT
ARQT
LSCC
LSCC
Q1 26
$145.8M
Q4 25
$129.5M
Q3 25
$99.2M
$133.3M
Q2 25
$81.5M
$124.0M
Q1 25
$65.8M
$120.2M
Q4 24
$71.4M
$117.4M
Q3 24
$44.8M
$127.1M
Q2 24
$30.9M
$124.1M
Net Profit
ARQT
ARQT
LSCC
LSCC
Q1 26
$-7.6M
Q4 25
$17.4M
Q3 25
$7.4M
$2.8M
Q2 25
$-15.9M
$2.9M
Q1 25
$-25.1M
$5.0M
Q4 24
$-10.8M
$16.5M
Q3 24
$-41.5M
$7.2M
Q2 24
$-52.3M
$22.6M
Gross Margin
ARQT
ARQT
LSCC
LSCC
Q1 26
68.5%
Q4 25
91.0%
Q3 25
91.2%
67.9%
Q2 25
90.8%
68.4%
Q1 25
86.6%
68.0%
Q4 24
90.3%
61.1%
Q3 24
87.7%
69.0%
Q2 24
88.8%
68.3%
Operating Margin
ARQT
ARQT
LSCC
LSCC
Q1 26
0.7%
Q4 25
14.2%
Q3 25
8.6%
-1.2%
Q2 25
-17.9%
3.8%
Q1 25
-37.3%
5.8%
Q4 24
-10.7%
-10.4%
Q3 24
-87.3%
5.9%
Q2 24
-162.3%
18.2%
Net Margin
ARQT
ARQT
LSCC
LSCC
Q1 26
-5.2%
Q4 25
13.4%
Q3 25
7.5%
2.1%
Q2 25
-19.5%
2.3%
Q1 25
-38.1%
4.2%
Q4 24
-15.1%
14.1%
Q3 24
-92.8%
5.7%
Q2 24
-169.6%
18.2%
EPS (diluted)
ARQT
ARQT
LSCC
LSCC
Q1 26
$-0.06
Q4 25
$0.14
Q3 25
$0.06
$0.02
Q2 25
$-0.13
$0.02
Q1 25
$-0.20
$0.04
Q4 24
$-0.09
$0.12
Q3 24
$-0.33
$0.05
Q2 24
$-0.42
$0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARQT
ARQT
LSCC
LSCC
Cash + ST InvestmentsLiquidity on hand
$42.9M
$133.9M
Total DebtLower is stronger
$109.0M
Stockholders' EquityBook value
$189.5M
$714.1M
Total Assets
$433.0M
Debt / EquityLower = less leverage
0.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARQT
ARQT
LSCC
LSCC
Q1 26
$133.9M
Q4 25
$42.9M
Q3 25
$47.1M
$117.9M
Q2 25
$72.7M
$107.2M
Q1 25
$53.1M
$127.6M
Q4 24
$71.3M
$136.3M
Q3 24
$134.9M
$124.3M
Q2 24
$84.3M
$109.2M
Total Debt
ARQT
ARQT
LSCC
LSCC
Q1 26
Q4 25
$109.0M
Q3 25
$108.5M
Q2 25
$108.0M
Q1 25
$107.6M
Q4 24
$107.2M
Q3 24
$204.6M
Q2 24
$203.8M
Stockholders' Equity
ARQT
ARQT
LSCC
LSCC
Q1 26
$714.1M
Q4 25
$189.5M
Q3 25
$158.1M
$706.4M
Q2 25
$139.0M
$687.0M
Q1 25
$142.7M
$707.9M
Q4 24
$157.5M
$710.9M
Q3 24
$156.6M
$703.5M
Q2 24
$186.4M
$698.8M
Total Assets
ARQT
ARQT
LSCC
LSCC
Q1 26
$883.1M
Q4 25
$433.0M
Q3 25
$371.0M
$844.4M
Q2 25
$352.4M
$808.6M
Q1 25
$344.1M
$823.6M
Q4 24
$348.9M
$843.9M
Q3 24
$437.4M
$853.7M
Q2 24
$444.8M
$827.5M
Debt / Equity
ARQT
ARQT
LSCC
LSCC
Q1 26
Q4 25
0.58×
Q3 25
0.69×
Q2 25
0.78×
Q1 25
0.75×
Q4 24
0.68×
Q3 24
1.31×
Q2 24
1.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARQT
ARQT
LSCC
LSCC
Operating Cash FlowLast quarter
$26.2M
$57.6M
Free Cash FlowOCF − Capex
$44.0M
FCF MarginFCF / Revenue
30.2%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.51×
TTM Free Cash FlowTrailing 4 quarters
$153.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARQT
ARQT
LSCC
LSCC
Q1 26
$57.6M
Q4 25
$26.2M
Q3 25
$-1.8M
$47.1M
Q2 25
$324.0K
$38.5M
Q1 25
$-30.4M
$31.9M
Q4 24
$-748.0K
$45.4M
Q3 24
$-34.7M
$44.0M
Q2 24
$-45.1M
$21.9M
Free Cash Flow
ARQT
ARQT
LSCC
LSCC
Q1 26
$44.0M
Q4 25
Q3 25
$34.0M
Q2 25
$246.0K
$31.3M
Q1 25
$-31.0M
$23.3M
Q4 24
$39.7M
Q3 24
$-34.8M
$39.4M
Q2 24
$14.8M
FCF Margin
ARQT
ARQT
LSCC
LSCC
Q1 26
30.2%
Q4 25
Q3 25
25.5%
Q2 25
0.3%
25.2%
Q1 25
-47.1%
19.4%
Q4 24
33.8%
Q3 24
-77.8%
31.0%
Q2 24
11.9%
Capex Intensity
ARQT
ARQT
LSCC
LSCC
Q1 26
9.3%
Q4 25
0.0%
Q3 25
0.0%
9.8%
Q2 25
0.1%
5.8%
Q1 25
0.9%
7.2%
Q4 24
0.0%
4.9%
Q3 24
0.3%
3.7%
Q2 24
0.0%
5.8%
Cash Conversion
ARQT
ARQT
LSCC
LSCC
Q1 26
Q4 25
1.51×
Q3 25
-0.24×
16.86×
Q2 25
13.23×
Q1 25
6.35×
Q4 24
2.75×
Q3 24
6.12×
Q2 24
0.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons